The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...
8hon MSN
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback